Annual Report 2025
Bayer Group Consolidated Income Statements

€ million

 

Note

 

2024

 

2025

Net sales

 

[6]

 

46,606

 

45,575

Cost of goods sold

 

 

 

(21,270)

 

(18,797)

Gross profit

 

 

 

25,336

 

26,778

Selling expenses

 

 

 

(13,364)

 

(12,549)

Research and development expenses

 

 

 

(6,209)

 

(5,769)

General administration expenses

 

 

 

(2,574)

 

(2,160)

Other operating income

 

[7]

 

1,779

 

1,802

Other operating expenses

 

[8]

 

(5,039)

 

(9,179)

EBIT1

 

 

 

(71)

 

(1,077)

Equity-method income (loss)

 

[10.1]

 

(132)

 

(44)

Financial income

 

 

 

545

 

507

Financial expenses

 

 

 

(2,676)

 

(2,515)

Financial result

 

[10]

 

(2,263)

 

(2,052)

Income before income taxes

 

 

 

(2,334)

 

(3,129)

Income taxes

 

[11]

 

(212)

 

(466)

Income after income taxes

 

 

 

(2,546)

 

(3,595)

of which attributable to noncontrolling interest

 

[12]

 

6

 

25

of which attributable to Bayer AG stockholders (net income)

 

 

 

(2,552)

 

(3,620)

 

 

 

 

 

 

Earnings per share

 

[13]

 

 

 

 

Basic

 

 

 

(2.60)

 

(3.68)

Diluted

 

 

 

(2.60)

 

(3.68)

1

For definition see A 2.3 “Alternative Performance Measures Used by the Bayer Group.”